Neurological Biomarkers Market

Neurological Biomarkers Market Is Estimated To Witness High Growth Owing To Increasing Demand for Early Diagnosis and Treatment


The global neurological biomarkers market is estimated to be valued at US$ 8,979.6 Mn in 2023 and is expected to exhibit a CAGR of 14.7% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
The neurological biomarkers market is gaining significant traction due to the increasing need for early diagnosis and treatment of neurological disorders. Biomarkers are measurable indicators that can be used to detect and evaluate the progression of diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, and traumatic brain injury. The advantages of neurological biomarkers include their ability to provide objective and accurate measurements, aid in diagnosis and prognosis, and facilitate personalized treatment plans. The growing prevalence of neurological disorders, coupled with advancements in biomarker technologies, is driving the demand for neurological biomarkers.

Market Key Trends:
One key trend in the neurological biomarkers market is the increasing focus on the development of non-invasive biomarkers. Non-invasive biomarkers are those that can be detected or measured without the need for invasive procedures such as biopsies or cerebrospinal fluid sampling. They offer numerous advantages, including reduced patient discomfort, lower costs, and the ability to monitor disease progression over time. Non-invasive biomarkers can be detected through techniques such as blood tests, imaging, and genetic analysis. The development of non-invasive biomarkers is expected to revolutionize the diagnosis and monitoring of neurological disorders, leading to better patient outcomes and improved treatment strategies.

PEST Analysis:

Political: The political landscape can have an impact on the neurological biomarkers market. Factors such as government regulations, policies, and funding for research and development can affect the growth of the market. For example, changes in healthcare policies or government budget allocation for neurological disorders can influence the demand for biomarker testing.

Economic: Economic factors play a crucial role in the growth of the neurological biomarkers market. Economic stability, disposable income, healthcare expenditure, and reimbursement policies can all influence the market. For instance, an increase in healthcare spending and favorable reimbursement policies can drive the market growth by increasing the accessibility and affordability of biomarker tests.

Social: Social factors also impact the demand for neurological biomarkers. Factors such as the awareness and perception of neurological disorders among the general population, cultural beliefs, and social stigma can affect the market. Increasing awareness campaigns and initiatives to reduce the stigma associated with neurological disorders can contribute to market growth.

Technological: Technological advancements are instrumental in shaping the neurological biomarkers market. Innovations in diagnostic techniques, testing methods, and biomarker discovery can significantly impact the market. For example, the development of new imaging techniques or genetic testing methods can drive the demand for biomarker testing.

Key Takeaways:

The Global Neurological Biomarkers Market Demand is expected to witness high growth, exhibiting a CAGR of 14.7% over the forecast period of 2023-2030. This growth can be attributed to several factors, such as the increasing prevalence of neurological disorders, rising demand for early diagnosis and personalized medicine, and advancements in biomarker research.

In terms of regional analysis, North America is projected to be the fastest-growing and dominating region in the neurological biomarkers market. This can be attributed to factors like a high prevalence of neurological disorders, well-established healthcare infrastructure, increasing R&D activities, and favorable government initiatives. Additionally, the presence of key market players in the region further contributes to its dominance.

Key players operating in the neurological biomarkers market are Abbott Laboratories, QIAGEN N.V., Myriad RBM, Thermo Fisher Scientific Inc., Athena Diagnostics, Bio-Rad Laboratories, Inc., AbaStar MDx, Inc., Acumen Pharmaceuticals, Banyan Biomarkers, Inc., Alseres Pharmaceuticals, Inc., Proteome Sciences, Immunarray Pvt. Ltd., Quanterix Corporation, Diagenic ASA, and Psynova Neurotech. These key players are actively involved in research and development activities, collaborations, mergers, and acquisitions to gain a competitive edge and expand their market presence.

Overall, the neurological biomarkers market is expected to grow significantly in the coming years, driven by factors such as increasing prevalence rates, technological advancements, and a rising demand for accurate and personalized diagnostics for neurological disorders.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it